MedTrace Logo

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

NCT03347110 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2023-12-01

Study results available
· View outcomes & findings →

Summary

This is a study to assess the long-term safety and tolerability of bimekizumab in subjects with psoriatic arthritis

Conditions

Interventions

DRUG

Bimekizumab

Bimekizumab at a prespecified dose.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · +1 8445992273 (UCB)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-22
Primary Completion
2020-10-29
Completion
2020-10-29
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Germany
  • Hungary
  • Poland
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03347110 on ClinicalTrials.gov